H1-antihistamines in asthma
H1-antihistamines in asthma
Histamine released from mast cells and basophils is an important mediator of airway inflammation in asthma, particularly in the development of the early allergic response. Although histamine has been shown to contribute significantly to the bronchoconstrictor response to allergen or exercise, leukotrienes are likely to play a more prominent role in these responses in asthma. The improved specificity, tolerability, and safety profile of the second-generation H1-antagonists associated with anti-inflammatory activities and bronchodilator activities, may contribute to relieve the symptoms of the upper and lower airways in patients with coexistent mild seasonal asthma and allergic rhinitis. Considering the global rise in the prevalence of allergy and asthma, the suggestion that H1-antagonists may delay the onset of asthma in infants is of considerable interest and merits further assessment. Although it is unlikely that monotherapy with most currently available H1-antagonists will provide significant clinical benefit in asthma, the potential of combined antihistamine and antileukotriene therapy may prove useful, particularly in subjects with poor compliance to inhaled corticosteroid therapy.
221-248
Lordan, J.L.
d63dce9d-b04e-4eb5-a251-ba0d12c443dc
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
2002
Lordan, J.L.
d63dce9d-b04e-4eb5-a251-ba0d12c443dc
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Lordan, J.L. and Holgate, S.T.
(2002)
H1-antihistamines in asthma.
Clinical Allergy and Immunology, 17, .
Abstract
Histamine released from mast cells and basophils is an important mediator of airway inflammation in asthma, particularly in the development of the early allergic response. Although histamine has been shown to contribute significantly to the bronchoconstrictor response to allergen or exercise, leukotrienes are likely to play a more prominent role in these responses in asthma. The improved specificity, tolerability, and safety profile of the second-generation H1-antagonists associated with anti-inflammatory activities and bronchodilator activities, may contribute to relieve the symptoms of the upper and lower airways in patients with coexistent mild seasonal asthma and allergic rhinitis. Considering the global rise in the prevalence of allergy and asthma, the suggestion that H1-antagonists may delay the onset of asthma in infants is of considerable interest and merits further assessment. Although it is unlikely that monotherapy with most currently available H1-antagonists will provide significant clinical benefit in asthma, the potential of combined antihistamine and antileukotriene therapy may prove useful, particularly in subjects with poor compliance to inhaled corticosteroid therapy.
This record has no associated files available for download.
More information
Published date: 2002
Identifiers
Local EPrints ID: 27235
URI: http://eprints.soton.ac.uk/id/eprint/27235
ISSN: 1075-7910
PURE UUID: 1124728e-34fc-4129-a277-81a87c4d3d69
Catalogue record
Date deposited: 28 Apr 2006
Last modified: 08 Jan 2022 01:03
Export record
Contributors
Author:
J.L. Lordan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics